Single nucleotide polymorphisms (SNPs) in the gene for multidrug resistance protein ABCG2, an erlotinib transporter, is a possible contributor to the interindividual variation observed in erlotinib pharmacokinetics and toxicity. Therefore, the aim was to study erlotinib efflux by ABCG2 wild-type (wt) and ABCG2 polymorphic variants in the K562 cell line. The chronic myeloid leukemia K562 cell line, neither expressing EGFR nor ABCG2, was transduced with vectors containing the ABCG2 wt, the SNPs: 34 G > A and 421 C > A, or with empty vector (K562/ve). ABCG2-expressing cells
were enriched using magnetic sorting and the expression was verified using flow cytometry. Intracellular erlotinib concentrations were analyzed by LC-MS/MS after incubation with 1 µmol/L erlotinib for 60 minutes. All recombinant cell lines were confirmed carriers of the vector and expressed ABCG2. Differences in intracellular erlotinib concentrations were observed between K562/ve and K562 ABCG2 wt and between K562/ve and K562 ABCG2 34G > A (both P ≤ .001, one-way ANOVA with Tukey HSD post hoc test), indicating that the cell lines carrying ABCG2 wt and ABCG2 34G > A actively transports erlotinib out of the cells. The ABCG2 34G > A cell line had a higher transport capacity compared with ABCG2 wt after adjusting for ABCG2 expression (P = .024, t test). No differences were observed between K562/ve and K562 ABCG2 421 C > A. Genetic polymorphism in the ABCG2 gene has an influence on the transport of erlotinib which can contribute to the observed variation in erlotinib pharmacokinetics and toxicity.
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| INTRODUC TI ON
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is used in the treatment of non-small cell lung cancer (NSCLC) patients harboring somatic EGFR mutations, including exon 19 deletion and exon 21 L858R substitution. 1 Erlotinib is a targeted therapy that is administered orally once daily. Large interindividual variation is observed in erlotinib pharmacokinetics. Plasma drug concentrations have been associated with adverse drug reactions, 2 which occurs in up to 75% of the patients, and overall survival. 3, 4 Additional understanding of the underlying variation in pharmacokinetic parameters involved in erlotinib treatment would be of interest. One possible contributor could be the variability in the activity of the transporter and multidrug resistance-associated protein ABCG2.
The membrane-associated protein ABCG2, also known as the breast cancer resistance protein (BCRP), belongs to the ATP-binding cassette (ABC) transporter family Horsey Aaron et al. 5 ABCG2 is a half-transporter that utilizes ATP hydrolysis to extrude endogenous substances as well as xenobiotics out of the cell by efflux. 6 Naturally, ABCG2 expression is prevalent in the small intestine, colon, liver, stem cells, and barrier tissues including brain, placenta, and testis. [7] [8] [9] [10] The protective function of ABCG2 is also utilized by cancerous cells.
In chemotherapy treatment, the overexpression of ABCG2 in tumors is associated with multidrug resistance (MDR) which leads to increased efflux and reduced intracellular accumulation of drugs in cancer cells Horsey Aaron et al. 5 Concentrations of erlotinib in tumors are found to vary between <5 nmol/L and 1.1 µmol/L. 11 The 40-fold variation in erlotinib tumor concentration might be due to large interindividual variability in transport activity. This variability in efflux might be caused by natural genetic variation in the ABCG2 gene which in turn can affect the ABCG2 efflux activity.
In general, the ABCG2 nonsynonymous single nucleotide polymorphisms (SNPs) 34 G > A (V12M) and 421 C > A (Q141K) are vastly studied. The ABCG2 421C > A polymorphism is known to generate a lower protein expression compared to ABCG2 wild type (wt), 12 while ABCG2 34 G > A shows expression levels comparable to ABCG2 wt. 13 Earlier ABCG2 in vitro studies with erlotinib have determined that erlotinib is an ABCG2 substrate and that ABCG2 wt is more efficient in transporting erlotinib compared to control cell lines. 14, 15 Additionally, erlotinib intracellular concentrations in an ABCG2 421 C > A carrying cell line were not different compared to the control cell line. 14 
| MATERIAL S AND ME THODS

| Drugs and chemicals
Reference substances for erlotinib and erlotinib-D6 were purchased from Toronto Research Chemicals. Acetonitrile (ACN) of LC-MS grade was purchased from Merck AB and methanol (MeOH) of HPLC grade from Thermo Fischer Scientific. Ammonium Acetate (AmAc) of analytical grade was obtained from Sigma Aldrich.
| Cell cultivation
The parental K562 cell line (ATCC-LCG Standards) and the transduced K562 cell lines were cultivated in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 2% penicillin/ streptomycin at 37°C with 5% CO 2 . The cells were maintained by replacement or addition of fresh media to a concentration of 200 000 cells/ml every 3-4 days. Cell culture reagents were obtained from Life Technologies. All cell lines were tested negative for mycoplasma infection.
| Transduction of the K562 cell line
The K562 cell line was considered to be a suitable modeling system to study how erlotinib is transported by ABCG2 as K562 naturally neither express ABCG2 nor EGFR (www.prote inatl as.org). 16 SNPs considered for selection were nonsynonymous SNPs, not resulting in a stop codon and with a minor allele frequency (MAF)> 0.02 in any population. The two selected SNPs, 34 G > A, and 421 C > A were predicted to be tolerated by SIFT and Poly-Phen 17, 18 and are present in >10% of the total population, Table 1. K562 was stably transduced with ABCG2 wt, the ABCG2 polymorphisms 34 G > A and 421 C > A, and empty vector as previously described. 19 Briefly, ABCG2 was cut out of the pCMV6-XL5 
| ABCG2 and EYFP expression
Enrichment of ABCG2-expressing cells was performed using magnetic sorting with microbeads conjugated to monoclonal anti-human 
| Intracellular accumulation
The cell lines were seeded at 400 000 cells/mL in a total volume of 5 mL and incubated with a final concentration of 1 µmol/L erlotinib. After 60 minutes of incubation at 37°C with 5% CO 2 the cells were transferred to a 15 mL tube and centrifuged at 1000g 
| LC-MS/MS analysis
| Statistical analysis
Statistical differences in intracellular concentrations between cell
lines were analyzed with one-way ANOVA and Tukey HSD post hoc test and differences in transport capacity normalized for ABCG2 expression were analyzed with Student's independent t test using the IBM SPSS Statistics, version 26 (IBM). 
| RE SULTS
| ABCG2 expression
| Quantification of erlotinib using LC-MS/MS
The performance of the LC-MS/MS method for the quantification of erlotinib was monitored in each run (n = 2). Precision and accuracy for erlotinib in all quality control samples were < 5% and between 92% and 108%, respectively. 
| Intracellular accumulation of erlotinib
| D ISCUSS I ON
In this project, we have studied erlotinib efflux by K562 cells carrying wild-type ABCG2 and the ABCG2 SNPs 34 G > A and 421 C > A. The intracellular concentrations in K562 ABCG2 wt and K562 ABCG2 34 were significantly lower compared to the K562/ve indicating that the two cell lines actively transport erlotinib out of the cell, Figure 3 . The K562
ABCG2 34 exhibited a higher transport capacity compared to K562
ABCG2 wt, when the intracellular concentrations were normalized to ABCG2 expression, due to lower ABCG2 expression in K562 ABCG2 34, meanwhile similar amounts of erlotinib were transported out of the cells, Figure 4 . This finding should be viewed with caution as this might be due to limitations of the modeling system. The intracellular erlotinib concentrations in K562 ABCG2 421 did not differ from K562/ve, and when normalized to ABCG2 expression, the ABCG2 transport capacity was widely spread and included negative values, Figures 3 and 4 .
The cell line used in this project, the chronic myeloid leukemia K562 cell line, expresses no or very low amounts of ABCG2 and EGFR (www.prote inatl as.org). 16 Therefore, K562 is a suitable model to solely study erlotinib transport as cell survival is not affected. This was probably due to the more successful transduction of the empty vector as it was smaller, 6.5kb, compared to the other vectors that additionally contained 4.5kb of ABCG2 cDNA. A more even distribution of EYFP expression among the cell lines would probably have been achieved if the size difference between the empty vector and the ABCG2 containing vectors had been smaller.
The two cell lines K562 ABCG2 wt and K562 ABCG2 34 exhibited significantly lower erlotinib intracellular concentrations indicating that erlotinib was actively transported out of the cells. It is in line with previous studies where ABCG2 34 showed similar expression levels and transport capacity as wild type in other studied substances. 13 It has previously been shown that 421C > A results in a lower ABCG2 expression. 12 Low ABCG2 expression was also observed for K562 ABCG2 421 in this study, but it may also be caused by the reduced plasmid content. The results in this study suggest that cells carrying the 421 C > A gene variant are less effective than those with ABCG2 wt and 34G > A to transport erlotinib out of the cell. Our results confirm earlier results that there is no difference between cells carrying the 421C > A and control cell line. 14 (MAF = 0.08), did not find the same results. 2 A possible reason for the lack of significance in the study by Rudin et al 2 could be due to the difference in the allele frequency among the studied populations.
In summary, we have studied the transport of erlotinib in the K562 cell lines transduced with ABCG2 wt and ABCG2 SNPs in this project. We have identified that erlotinib efflux is affected by SNPs in ABCG2 which leads to variation in intracellular concentrations.
The results obtained in this study indicate that K562 ABCG2 wt and K562 ABCG2 34 actively transports erlotinib by efflux while K562
ABCG2 421 exhibits a reduced erlotinib transport capacity. ABCG2 polymorphism can, therefore, be considered as a possible contributor to the interindividual variation observed in erlotinib pharmacokinetics and toxicity.
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